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Abstract 
In this case report, we describe a rare case of a 32-year-old man who presented a highly 
aggressive, fast growing anaplastic oligodendroglioma five years after being treated with 
whole brain radiotherapy for a CNS recurrence of a lymphoblastic lymphoma. Initially, 
the patient was submitted to a surgical intervention and partial tumor resection, which 
allowed us to establish the pathologic diagnosis and the presence of a 1p deletion. 
Shortly after the operation the tumor grew back, exerting important mass effect. Since 
no radiation therapy or surgery could be used and the patient faced a critical condition, 
chemotherapy was started with a combination of temozolomide and bevacizumab. 
Immediately after the first cycle a marked clinical and radiological improvement was 
documented. 
 
Background 
Oligodendroglial tumors have generated a large amount of interest over the past years 
due to their heightened response to chemotherapy and ability to be divided into 
prognostic subgroups based on molecular biology [1]. Several clinical studies 
demonstrated that losses of portions of chromosomes 1p and 19q are associated with the 
oligodendroglial phenotype and longer recurrence-free survival following radiation 
and/or chemotherapy [2, 3]. It is believed that these chromosome regions contain tumor 
suppressor genes that block the development and/or progression of the tumor. Radiation  
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therapy inducing secondary oligodendroglial tumors are very rare [4], the approximate 
cumulative risk for secondary brain tumors after cranial irradiation is 1–3% [5]. Only a 
small portion of these rare tumors correspond to oligodendroglial histology; there have 
been less than 10 cases reported to date [4]. 
Case Report 
A 32-year-old man was admitted to the Hospital Sírio-Libanês in June 2008 with a short history of 
progressive headache and left hemiplegia. The patient had a previous history of a lymphoblastic 
lymphoma with central nervous system involvement, and had been previously submitted to a variety of 
systemic chemotherapy regimens, including an autologous bone marrow transplantation in June 2002. 
Six months after that procedure the patient developed a CNS recurrence and was treated with radiation 
therapy which encompassed the whole brain and the neuraxis (24 Gy administered in 12 fractions), 
achieving a complete remission. The patient remained well and asymptomatic, without any clinical or 
radiological evidences of lymphoma up until shortly prior to this hospital admission, when a brain MRI 
was performed, showing a gross mass in the right temporal lobe (fig. 1a, b). A partial tumor resection 
was carried out and the pathologic evaluation, based on histology and immunohistochemistry, ruled out 
the possibility of recurrence of the lymphoma and revealed the presence of an anaplastic 
oligodendroglioma. The pathologic specimen was reviewed by 3 different pathologists, who concurred 
with this diagnosis. A FISH assay was performed and showed the presence of 1p deletion, but not 19q 
deletion. During the postoperative period the patient developed a rapid neurologic deterioration (PS:4, 
complete left hemiplegia, severe headaches). As shown in the MRI performed after the surgical 
procedure, the tumor had rapidly increased in size (fig. 1c, d). Given the dramatic clinical course and 
tumor development, we decided to treat the patient with temozolomide at a dose of 150 mg/m
2/day for 
5 consecutive days every 28 days associated with bevacizumab at a dose of 10 mg/kg given on days 1 and 
15. Shortly after the treatment was started, the patient’s neurological condition markedly improved. Six 
weeks after starting this therapy the patient was walking with the help of a cane and the MRI showed a 
complete resolution of the mass effect and a complete disappearance of the contrast-enhancing tumor 
(fig. 1e, f). 
Discussion 
The classic treatment for patients with a newly-diagnosed anaplastic oligodendroglial 
tumor is based on maximal surgical resection consistent with preservation of neurologic 
function [6]. Radiotherapy should be used in patients with large residual mass or with 
anaplastic lesions [7]. For selected cases with deletions in 1p and 19q, chemotherapy 
should also be considered, either in conjunction with radiotherapy or as a single modality 
[7, 8]. In our patient the usual approach could not be applied. An adequate tumor 
resection was not possible because of the size and location of the tumor, which also 
involved the contralateral hemisphere. In addition, radiation therapy was also not an 
option due to whole brain irradiation previously administered. 
Temozolomide is a broadly utilized oral methylating agent. The activity of this drug in 
the treatment of high grade gliomas is well recognized. In phase II trials, temozolomide as 
single agent produces response rates of 50–60% in patients with anaplastic 
oligodendroglioma [9, 10]. There are no randomized trials evaluating the role of 
temozolomide in oligodendroglial tumors. 
Bevacizumab is a monoclonal antibody with important anti-angiogenic properties, 
which inhibits the serum vascular endothelial growth factor (VEGF), a cystine-knot 
growth factor involved in vasculogenesis. In phase II trials, bevacizumab showed 
important activity and safety in patients with high-grade glioma [11, 12]. Recent data 
suggest that the combination of temozolomide and Bevacizumab is active in high-grade  
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gliomas with an acceptable safety profile even when given with concomitant radiotherapy 
[13, 14]. 
The quick and significant tumor reduction seen in this patient constitutes, to our 
knowledge, the first report of the use of this form of therapy in an anaplastic 
oligodendroglioma patient. Given the previous medical history of this patient and the 
rapid pace of tumor growth, we were afraid that unless the initial treatment could induce 
important and fast tumor regression, a life-threatening condition would be reached 
within a matter of days. 
 
 
 
 
 
Fig. 1. Seriated MRI analysis showing tumor progression and reduction over time. a, b Exam 
performed on 17/07/08 showing a large mass compromising temporal, parietal and occipital lobes on 
the T1 contrasted sequence (a) and on the flair sequence (b). c, d Exam performed on 04/08/08 showing 
a marked increase in tumor size in a short interval, on the contrasted T1 sequence (c) and on the flair 
sequence (d). e, f Exam performed on 15/09/08, 2 weeks after the second dose of temozolomide was 
administered, showing a complete disappearance of the contrast-enhancing mass and resolution of the 
mass effect on the contrasted T1 sequence (e) and on the flair sequence (f). 
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